Research

Breadcrumb trail

Need Help or want to give your feedback?

Whether you’re having trouble with your account, or would like to make a suggestion, Canadian Blood Services offers you quick and convenient options to troubleshoot or get in touch. Contact us via live chat, consult our FAQ, send an email feedback@blood.ca, or give us a call at 1 888 2 DONATE (1-888-236-6283).

Novel cell-surface engineering methods to increase immune-tolerance of allogenic cell transplantation

Principal Investigator / Supervisor: 
KIZHAKKEDATHU, Jayachandran
Co-Investigator(s) / Trainee: 
MOON, Haisle
Institution: 
University of British Columbia
Province: 
British Columbia
Project Start Date: 
April 15, 2017
Project End Date: 
April 14, 2019
Summary: 
Blood transfusion treats a number of acute and chronic medical problems. In transfusion therapy, unintentional mismatching of red blood cells (RBC) for blood groups remains one of the most common causes of serious and sometimes fatal adverse reactions. In addition, shortage of blood supply in rare blood transfusion and development of alloimmunization in patients undergoing chronic blood transfusions still remains as major challenges to our blood bank system. In the current proposal, this unmet clinical need in blood cell transfusion will be addressed by 1) developing a novel enzyme mediated RBC-surface grafting method, 2) utilizing ‘Factor H’ (negative regulator of complement system—part of innate immune response) binding peptide functionalized hyper-branched polyglycerols (HPG) polymers to protect antigenic sites on the RBC-membrane, and 3) developing combination strategy utilizing polymer grafting to protect minor blood group antigens and enzymatic cleavage of carbohydrate AB antigens to generate truly universal donor RBCs. Such developments would significantly improve the blood supply and increase transfusion safety by successfully modulating the interaction between the modified cells and host immune system. Further, the newly developed method will be applicable in other forms of transplantation medicine by minimizing the adverse immune reaction; hence, evade subsequent rejection or removal. *Cofunded through a MITACs fellowship
Total Amount Awarded: 
$30,000
Program: 
National Training Program

Projects summaries are contributed by investigators who receive financial support from Canadian Blood Services. The summaries are intended to inform the public of the types of research projects that are supported by our organization. The information described in project summaries should not be considered as recommendation for clinical treatment and diagnosis.